Bemotrizinol is the first new chemical UV filter approved for U.S. sunscreens in nearly three decades, and unlike avobenzone — the UVA filter in most American bottles — it is photostable, meaning it does not break down after sun exposure.
For the first time in nearly three decades, the FDA has approved a new chemical UV filter for sunscreens sold in the United States — and dermatologists say it does something the existing American options do not: it stays effective in the sun. (Note: NPR's reporting on the approval characterizes this as the first such filter in "nearly three decades," though the article also contains a body-text reference to "first time in 20 years." The draft adopts the "nearly three decades" framing from the article's headline and subhed; Giskard should verify the precise prior-approval date against a primary FDA record to confirm the directional accuracy of this claim.)
The ingredient, bemotrizinol, was greenlit by the agency in June, according to NPR's reporting, which cited the FDA's action. It is the first new organic UV-absorbing active, the category of ingredients that work by soaking up ultraviolet radiation rather than sitting on the skin and reflecting it, to clear U.S. regulators since the 1990s. European and Asian sunscreen makers have used bemotrizinol for years; getting it past the FDA took the manufacturer, the Swiss-Dutch ingredients firm DSM-Firmenich, more than two decades and at least $18 million. (The $18-million figure is manufacturer-stated.)
The reason the approval matters goes beyond a single chemical. Today's American chemical sunscreens lean heavily on avobenzone to handle UVA, the longer-wavelength rays that age skin, deepen wrinkles, and penetrate glass, while a separate filter, usually octisalate or octocrylene, handles UVB, the shorter rays that cause sunburn. Avobenzone works, but it has a well-known weakness: it is photounstable, meaning the molecule breaks down under UV exposure. Within a couple of hours in real sun, much of its UVA protection is gone, and the breakdown products can irritate skin.
Dr. Heather Rogers, a board-certified dermatologist in Seattle and fellow of the American Academy of Dermatology, told NPR that bemotrizinol is photostable: it does not fall apart in sunlight. That single property is what makes the new ingredient a structural upgrade rather than a minor reformulation.
It is also broad-spectrum in one molecule. Bemotrizinol absorbs both UVA and UVB, which means formulators do not have to combine as many active ingredients to hit the "broad spectrum" line on a label. The result, cosmetic chemist Kelly Dobos of the University of Cincinnati told NPR, is the potential for lighter, less greasy formulas that do not leave the white cast of zinc oxide and titanium dioxide mineral sunscreens behind.
Safety data reviewed by the FDA included animal studies that turned up no reproductive-harm signals and human clinical trials that found no skin irritation even with repeated application. Bemotrizinol's molecular size also keeps it from being readily absorbed into the bloodstream, a contrast with several older chemical UV filters that have shown measurable blood levels in past FDA studies and that have helped fuel the recent sunscreen backlash on social media.
That backlash, and the broader, long-running debate about chemical sunscreen safety, is part of the backdrop, not the lead. The more durable question is what the approval signals for the rest of the FDA's queue. A dozen or more next-generation UV filters have been waiting for years under the same over-the-counter drug review pathway that held up bemotrizinol. If the agency treats this approval as a template, the regulatory bottleneck that kept American sunscreens a generation behind European and Asian formulas may be starting to crack.
For consumers, the practical impact will take time. DSM-Firmenich has 18 months of exclusive U.S. marketing rights and will sell the ingredient under the brand name Parsol Shield. Reformulated products are expected to reach U.S. store shelves around September. They will carry the same "broad spectrum" designation as existing sunscreens, meaning they have passed an FDA test for UVA protection. The active name on the back of the bottle is the giveaway: if bemotrizinol appears in the drug facts panel, the formula is using the new filter.
A few things remain genuinely unresolved. Reformulators will still need to combine bemotrizinol with other actives to hit the SPF numbers consumers expect, and the retail price of the first Parsol Shield products has not been disclosed. "Larger and more elegant" is not the same as "cheaper," Alexa Friedman, a senior scientist at the Environmental Working Group, told NPR. Until the first bottles land and the receipts come in, the real-world difference between the new chemistry and the old chemistry will be a label-reading exercise more than a price comparison.
That is the part worth watching. The FDA has shown it can move a long-pending UV filter through the system, and the industry has an incentive to keep the door open. The next few approvals will tell consumers and dermatologists whether this is a one-off or the start of a wider catch-up.